We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Roche Expands Obesity Pipeline With Rona's RNAi Candidate
Read MoreHide Full Article
Key Takeaways
Roche secures worldwide rights to Rona's investigational ALK7-targeting RNAi candidate for obesity.
The deal includes up to $100 million in upfront and near-term milestones, plus $1.06B in potential payments.
Roche advances enicepatide in Phase III trials but faces strong competition from Eli Lilly and Novo Nordisk.
Swiss pharma giant Roche (RHHBY - Free Report) is expanding its obesity and metabolic disease pipeline through an exclusive worldwide licensing agreement with Rona Therapeutics for an investigational RNA interference (RNAi) candidate targeting activin receptor-like kinase 7 (ALK7).
The deal reinforces Roche’s focus on developing next-generation treatments for obesity, a market with growing demand for differentiated therapies.
Year to date, shares of Roche have risen 4.3% compared with the industry’s growth of 13%.
Image Source: Zacks Investment Research
Rationale Behind RHHBY’s Deal With Rona
ALK7, encoded by the ACVR1C gene, is predominantly expressed in adipose tissue and is a genetically validated target for obesity and metabolic diseases. Inhibiting ALK7 directly in adipocytes could help reduce visceral and other ectopic fat deposits while preserving lean muscle mass and improving metabolic health.
The candidate offers a differentiated mechanism from incretin-based obesity drugs. ALK7 inhibition instead targets adipose tissue biology, potentially enabling its use as a standalone treatment or in combination with established obesity therapies.
Under the agreement, Rona will receive upfront and near-term milestone payments of up to $100 million and is eligible for up to $1.06 billion in potential development, regulatory and commercial milestone payments, along with tiered royalties on global net sales.
For Roche, the collaboration strengthens its cardiovascular, renal and metabolic pipeline and provides access to a novel RNAi approach to obesity.
While the partnership expands Roche's long-term growth opportunities in metabolic disease, the candidate's early-stage nature limits near-term revenue visibility.
Last month, Roche reported encouraging top-line results from a mid-stage study of enicepatide (CT-388), its investigational once-weekly dual GLP-1/GIP receptor agonist, in adults with type 2 diabetes (T2D) and overweight or obesity.
Enicepatide met both primary endpoints at 48 weeks, delivering dose-dependent reductions in HbA1c and body weight.
These encouraging results strengthen Roche’s prospects of establishing a foothold in the rapidly expanding obesity and metabolic disease market.
The efficacy profile is encouraging as Roche seeks to compete in the increasingly crowded incretin market, which includes established therapies from Eli Lilly (LLY - Free Report) and Novo Nordisk (NVO - Free Report) .
Roche is advancing a broad late-stage development program for enicepatide, with two ongoing phase III studies in chronic weight management (ENITH-1 and ENITH-2). The company plans to initiate a phase III glycemic-control program and cardiovascular outcomes trials in the first half of 2027.
Eli Lilly currently leads the obesity market with its tirzepatide-based dual GLP-1/GIP receptor agonists, Mounjaro and Zepbound.
LLY’s arch rival Novo Nordisk also commands a strong position with its semaglutide-based GLP-1 therapies, Ozempic and Wegovy, which are used to treat type 2 diabetes and obesity.
With LLY and NVO deriving a significant portion of their revenues from cardiometabolic medicines, Roche faces an uphill battle to gain meaningful market share despite its expanding late-stage pipeline.
RHHBY’s Efforts to Diversify Pipeline
Strong growth from key drugs like Ocrevus, Vabysmo, Hemlibra and Phesgo has helped RHHBY offset declining revenues from legacy drugs.
Roche has a strong and diversified pipeline spanning multiple therapeutic modalities.
The FDA recently accepted the company’s new drug application (NDA) under priority review for fenebrutinib, an investigational non-covalent Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
Upon approval, fenebrutinib would become the first BTK inhibitor and first high-efficacy oral treatment for both RMS and PPMS.
RHHBY recently reported positive prespecified interim results from the ongoing phase III IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA nephropathy.
The study met its primary endpoint, with sefaxersen demonstrating statistically significant and clinically meaningful reductions in proteinuria compared with placebo at 37 weeks, as measured by the 24-hour urine protein-to-creatinine ratio.
View the Zacks #1 Rank List
Image: Bigstock
Roche Expands Obesity Pipeline With Rona's RNAi Candidate
Key Takeaways
Swiss pharma giant Roche (RHHBY - Free Report) is expanding its obesity and metabolic disease pipeline through an exclusive worldwide licensing agreement with Rona Therapeutics for an investigational RNA interference (RNAi) candidate targeting activin receptor-like kinase 7 (ALK7).
The deal reinforces Roche’s focus on developing next-generation treatments for obesity, a market with growing demand for differentiated therapies.
Year to date, shares of Roche have risen 4.3% compared with the industry’s growth of 13%.
Image Source: Zacks Investment Research
Rationale Behind RHHBY’s Deal With Rona
ALK7, encoded by the ACVR1C gene, is predominantly expressed in adipose tissue and is a genetically validated target for obesity and metabolic diseases. Inhibiting ALK7 directly in adipocytes could help reduce visceral and other ectopic fat deposits while preserving lean muscle mass and improving metabolic health.
The candidate offers a differentiated mechanism from incretin-based obesity drugs. ALK7 inhibition instead targets adipose tissue biology, potentially enabling its use as a standalone treatment or in combination with established obesity therapies.
Under the agreement, Rona will receive upfront and near-term milestone payments of up to $100 million and is eligible for up to $1.06 billion in potential development, regulatory and commercial milestone payments, along with tiered royalties on global net sales.
For Roche, the collaboration strengthens its cardiovascular, renal and metabolic pipeline and provides access to a novel RNAi approach to obesity.
While the partnership expands Roche's long-term growth opportunities in metabolic disease, the candidate's early-stage nature limits near-term revenue visibility.
Last month, Roche reported encouraging top-line results from a mid-stage study of enicepatide (CT-388), its investigational once-weekly dual GLP-1/GIP receptor agonist, in adults with type 2 diabetes (T2D) and overweight or obesity.
Enicepatide met both primary endpoints at 48 weeks, delivering dose-dependent reductions in HbA1c and body weight.
These encouraging results strengthen Roche’s prospects of establishing a foothold in the rapidly expanding obesity and metabolic disease market.
The efficacy profile is encouraging as Roche seeks to compete in the increasingly crowded incretin market, which includes established therapies from Eli Lilly (LLY - Free Report) and Novo Nordisk (NVO - Free Report) .
Roche is advancing a broad late-stage development program for enicepatide, with two ongoing phase III studies in chronic weight management (ENITH-1 and ENITH-2). The company plans to initiate a phase III glycemic-control program and cardiovascular outcomes trials in the first half of 2027.
Eli Lilly currently leads the obesity market with its tirzepatide-based dual GLP-1/GIP receptor agonists, Mounjaro and Zepbound.
LLY’s arch rival Novo Nordisk also commands a strong position with its semaglutide-based GLP-1 therapies, Ozempic and Wegovy, which are used to treat type 2 diabetes and obesity.
With LLY and NVO deriving a significant portion of their revenues from cardiometabolic medicines, Roche faces an uphill battle to gain meaningful market share despite its expanding late-stage pipeline.
RHHBY’s Efforts to Diversify Pipeline
Strong growth from key drugs like Ocrevus, Vabysmo, Hemlibra and Phesgo has helped RHHBY offset declining revenues from legacy drugs.
Roche has a strong and diversified pipeline spanning multiple therapeutic modalities.
The FDA recently accepted the company’s new drug application (NDA) under priority review for fenebrutinib, an investigational non-covalent Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
Upon approval, fenebrutinib would become the first BTK inhibitor and first high-efficacy oral treatment for both RMS and PPMS.
RHHBY recently reported positive prespecified interim results from the ongoing phase III IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA nephropathy.
The study met its primary endpoint, with sefaxersen demonstrating statistically significant and clinically meaningful reductions in proteinuria compared with placebo at 37 weeks, as measured by the 24-hour urine protein-to-creatinine ratio.
RHHBY’s Zacks Rank and Stocks to Consider
Roche currently has a Zacks Rank #4 (Sell).
A better-ranked large cap pharma stock is Bayer (BAYRY - Free Report) , which currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Shares of Bayer have gained 13.9% year to date. Estimates for BAYRY’s 2026 EPS have increased from $1.28 to $1.29 over the past 60 days.